For a limited time, the AST is offering an exclusive membership discount to transplant trainees. We're on a mission to help trainees boost their careers using the AST's benefits.

Through March 31, 2025, trainees can join the AST for just $60. To join with this promotion, you must qualify as a transplant trainee and be approved for membership. To receive the discount, use code TRAINEE2025.

Join us at the 2025 Cutting Edge of Transplantation (CEoT) – Transforming Tomorrow: Leading the Way in Organ Transplantation Modernization – from February 27 to March 1 in Scottsdale, AZ. Register today to be part of the future of transplantation.

The Fellow of the American Society of Transplantation (FAST) designation application is now open to all members who meet the eligibility criteria. Don't miss out on joining this prestigious program and be recognized for your contributions to transplantation!

On behalf of the PSECOP and WHCOP, we would like to invite you to participate in a quick survey entitled Gender Identity Knowledge Among Transplant Professionals.

The aim of the survey is to understand providers’ knowledge and experience providing care to LGBTQ+ identifying patients. Providers include all those who participate in the transplant process, including but not limited to advanced care providers (APPs), coordinators, ethicists, nurses, pharmacists, psychologists, physicians, and surgeons.

The survey has been approved by the AST Education Committee. It will take 5-10 minutes to complete.

Thank you in advance for your time and participation.

The AST Public Policy Committee is pleased to introduce the AST Public Policy Form, a survey aimed at soliciting your perspectives on legislative and regulatory issues that significantly influence both patient care and professional practice. With this new initiative, our goal is to establish a platform for our membership to actively engage with the Public Policy Committee by sharing their invaluable ideas and perspectives. We look forward to your input as we navigate the dynamics of our ever-evolving landscape of transplant care and practice.

Respiratory syncytial virus (RSV) infection causes high morbidity in immunocompromised persons.1 Novel prefusion F (preF)–containing RSV vaccines showed 13- to 14-fold increases in antibody titers one month after vaccination and 82.6% efficacy against confirmed RSV-related lower respiratory tract disease in immunocompetent populations.

New therapies directed against plasma cells such as anti-CD38 antibodies and the bispecific anti–B cell maturation antigen antibodies, represent not only an important advance in the treatment of multiple myeloma but have the potential to change the treatment landscape of other antibody-mediated diseases.

A Randomized Trial in the Southeastern United States